



# NHI Medical Review and Medi-Cloud System in Taiwan

**Medical Review and Pharmaceutical Benefits Division**

**Wen-Fu Tseng, Senior Executive Officer**

**2017.07.27**



National Health Insurance Administration  
Ministry of Health and Welfare, Taiwan




# *Outline*

- NHI Characteristics of Taiwan
- Medical Review Organization and Mechanism
  - Adjudication Check
  - Profile Analysis
  - Peer Review
- NHI Medi-Cloud System



# Profile of Taiwan (2015)

Population	23.49 million
Land area	36,193km <sup>2</sup>
Ageing (Over 65)	12.5%
GDP per capita	US\$ 22,294 (nominal) US\$ 46,800 (PPP, est. from CIA)
Crude birth rate (2014)	9.00 ‰
Crude death rate (2014)	7.00‰
Infant mortality	4.1 ‰
Maternal mortality	11.7 0/0000
NHE to GDP (2014)	6.2%
Life expectancy(2014)	83.2 (F) / 76.7(M)






# NHI Characteristics

Coverage	Compulsory enrollment for all citizens and legal residents (99.9% of the population is covered by the NHI)
Administration	Single-payer system run by the government
Financing	Premiums
Benefits	Uniform package, copayment required
Providers	Contract-based 93.03% of healthcare providers contracted with NHI
Payment	Plural payment programs under the global budget payment systems
Privileges	Premium subsidies and copayment waivers for the disadvantaged



# National Health Insurance Organizational Chart





# **Medical Review Organization and Mechanism**



# Purpose of Medical Review

---


To ensure

- the right services are provided by the contracted medical institutions
- the right amount is paid by the insurer
- the medical services provided is good quality

(Article 63, NHI Law)




# Medical Review Organizations







# Flow Chart of Medical Claims Processing & Review





# Adjudication Check

- Eligibility of the insured
- NHI Benefit Scope
- Fee Schedule and Pharmaceutical Benefit Scheme adjudication rules
  - Price check
  - Physician Specialty check
  - gender-age check
- Number of adjudication rules : 2082



# Profile Analysis

- Promote the efficiency of professional review and medical quality
  - Detect outlier providers for further review
  - Provide reference information to aid peer review
- Feedback information to contracted medical institutions
- Publicly disclose information of medical quality indicators



## *Data-Analysis system (DA system)*

*-Build a clearinghouse of medical utilization  
and quality indicators from claims data-*



## *Major Contents of DA System*

---

Clearinghouse of medical utilization and quality indicators

(around 760 indicators so far)

- Medical quality monitoring indicators under 5 global budget sectors
- Disease-specific quality indicators
- Indicators of P4P pilot program
- Other monitoring indicators
  - Drug safety and utilization indicators
  - DRG related indicators
  - NHI-MediCloud indicators



# Indicators of Profile Analysis

Division of GB	Examples of indicators
Hospital	<ol style="list-style-type: none"><li>1.14-day readmission rates</li><li>2.Antibiotics usage of ambulatory services</li></ol>
Clinic	<ol style="list-style-type: none"><li>1.Duplication rate of antacid per visit</li><li>2.Injection medicine usage for ambulatory services</li></ol>
Dental care	<ol style="list-style-type: none"><li>1.Endodontic treatment complete rate within 90 days</li><li>2. Full mouth scaling rate for 13 years up</li></ol>
Chinese medicine	<ol style="list-style-type: none"><li>1.Duplication visit in the same day</li><li>2.Duplication rate of Chinese medicine drugs in the same day</li></ol>
Dialysis	<ol style="list-style-type: none"><li>1.Peritoneal infection rate</li><li>2.A-V shunt reconstruction rate</li><li>3. Hct</li></ol>



# Disease-specific Indicators

---

Disease	Examples of indicators
Total knee replacement	Infection rate of surgery
Hypertension	<ol style="list-style-type: none"><li>1. Duplication rate of hypertensive drugs in the same day</li><li>2. Thiazide diuretics usage of hypertensive patients with gout</li></ol>
Asthma	<ol style="list-style-type: none"><li>1. Readmission rate of Asthma patient</li><li>2. Admission rate of Asthma patient under 6 years</li></ol>
Mental illness	<ol style="list-style-type: none"><li>1. Ambulatory follow-up of mental illness patient within 30 days of discharge</li><li>2. Duplication rate of Anti-schizophrenia drugs in the same day</li></ol>




# Screenshot of DA system (1/3)

網域樹狀結構

- 01\_醫療服務指標
  - 標準報表
    - 01.各總額別
    - 02.品質確保方案
    - 03.院所別醫療品質資訊公開
    - 04.疾病別
    - 05.醫療給付試辦方案
    - 06.TWDRGS指標
    - 07.OECD指標
    - 08.監理會支出情形報告監測指標
    - 09.績效衡量指標
    - 10.季報(品保方案專業醫療服務品質指標)
    - 11.年報(品保方案專業醫療服務品質指標)
    - 12.其他醫療品質監控管理指標
    - 13.急診品質提升方案
    - 14.品質保證保留款
    - 15.明細報表查詢
    - 16.醫療服務指標查詢作業(PHET8000)
    - 17.慢性透析病人歸人檔
    - 18.健保會業務執行報告
    - 97.指標警示報表
    - 98.彙算進度查詢
    - 99.暫停產製區(退場指標)

- 02\_藥品監測報表
  - 標準報表
    - 01.藥品監測報表-月
    - 02.藥品監測報表-季
    - 03.藥品監測報表-半年
    - 04.藥品監測報表-年
    - 05.三大案件用藥
- 03\_特材監測報表
  - 標準報表
    - 01.整體監控
    - 02.醫令監控
- 05\_雲端藥歷效益評估報表
  - 標準報表
    - 01.系統查詢使用率報表
    - 02.效益評估報表







# Screenshot of DA system (2/3)

網域樹狀結構

- 網域
  - 01\_醫療服務指標
    - 標準報表
      - 01\_各總額別
        - 01\_醫院總額
          - 0001\_上呼吸道感染病人複診率(一)
          - 0002\_上呼吸道感染病人複診率(二)
          - 0003\_西醫重複就診率(一)
          - 0006\_平均每張處方箋開藥天數
          - 0007\_一般處方每張處方用藥品項數
          - 0008\_慢性病每張處方用藥品項數
          - 0009\_平均每張處方藥用藥品項數
          - 0010\_注射劑使用率
          - 0012\_整體用藥日數重複率
          - 0013\_同一院所用藥日數重複率
          - 0014\_開立慢性病連續處方箋百分比(一)
          - 0015\_慢性病開立慢性病連續處方箋百分比(一)
          - 0016.01\_處方箋釋出率
          - 0016\_處方箋釋出率
          - 0017\_上呼吸道感染抗生素使用率
          - 0018\_十四日內再住院率、三日內再急診率
          - 0020.01\_使用FSWI病人平均利用人次

List of indicators  
In specific category

歡迎使用, NHIUSER2

登出 | 樹狀結構



中央健康保險署  
National Health Insurance Administration

報表檢視

指標查詢

DA最新公告

參數

維度(0001)

請輸入費用年季(起) (YYQN 例如: 99Q1)

請輸入費用年季(迄)

輸出格式

分區

Branch division

Enter statistical duration  
that want to inquire

Select output  
data  
format

執行 重設 清除輸出

在新的視窗中執行

Enter the parameter and  
get report



# Screenshot of DA system (3/3)

Rate of hospital readmission within 14 days after hospital discharge

Rate of ER visits within 3 days after hospital discharge

18筆記錄 (共 18筆記錄), 第 1 頁 (共 1 頁)

編號: DA0180200

衛生福利部中央健康保險署 醫療服務指標

十四日內再住院率、三日內再急診率

[分區]

參數:

年季 (起): 103Q1

Case No. of ER visit

readmission rate within 14 days

Branch division

Case No. of 14-day re-admission

Case No. of discharge

Rate of ER visits within 3 days

頁數: 1/1

業務組名稱	年季	十四日內再住院案件數	三日內再急診案件數	出院案件數	十四日內再住院率	三日內再急診率
臺北業務組	103Q1	26,766	7,833	216,786	12.35%	3.61%
	103Q2	29,182	8,366	229,078	12.74%	3.65%
	103Q3	29,414	8,610	233,800	12.58%	3.68%
北區業務組	103Q1	8,892	2,971	97,164	9.15%	3.06%
	103Q2	9,714	3,355	103,396	9.39%	3.24%
	103Q3	9,863	3,774	105,363	9.36%	3.58%
中區業務組	103Q1	17,411	5,937	144,198	12.07%	4.12%
	103Q2	17,890	6,043	150,551	11.88%	4.01%
	103Q3	18,384	6,213	153,694	11.96%	4.04%
南區業務組	103Q1	12,785	3,349	106,650	11.99%	3.14%
	103Q2	13,867	3,549	112,211	12.36%	3.16%
	103Q3	13,767	3,438	113,368	12.14%	3.03%
高屏業務組	103Q1	11,242	3,321	118,944	9.45%	2.79%
	103Q2	11,965	3,498	123,890	9.66%	2.82%
	103Q3	12,527	3,541	126,997	9.86%	2.79%
東區業務組	103Q1	2,484	878	19,739	12.58%	4.45%
	103Q2	2,448	988	20,566	11.90%	4.80%
	103Q3	2,451	997	20,255	12.10%	4.92%

十四日內再住院率 By 業務組名稱




π chart

- 中區業務組 17.6%
- 北區業務組 13.7%
- 南區業務組 17.9%
- 東區業務組 18%
- 臺北業務組 18.5%
- 高屏業務組 14.2%

出院案件數 By 出院案件數

總和

出院案件數 By 出院案件數



Bar chart



# Peer Review


- Mechanism
  - Sampling review
- Reason
  - Number of claims is too huge to review each case :  
30 million outpatient claims/ 0.26 million inpatient claims per month
- Purpose
  - Save manpower, time, costs, and increase efficiency
- Method
  - Random sampling deduction rate will be extrapolated to the denominator at the same ratio



# Principle of Random Sampling

	No. of Claims	Sampling Rate
Western Medicine Chinese Medicine		1/100
Dental Care	1-1000	1/10
	1001 above	1/20
Inpatient		1/15

# Medical Claim, Review and Appeal Process



# NHI Medi-Cloud System



# Feature of NHI-MediCloud, Taiwan(1)

---

1. Established in July 2013
2. A patient-centered health insurance medical record information system
3. With minimal cost of establishment
4. Updates the information on a rolling daily basis
5. Takes about 10-15 seconds to display the information






## Feature of NHI-MediCloud, Taiwan(2)

6. Allows authorized medical practitioners to request and receive up-to-date medical records of patient
7. Subject to strict privacy and security measures designed to prevent unauthorized access
8. Health professionals can only view the information but can not extract the data
9. Keeps log files to track and evaluate the outcomes





# NHI Medi-Cloud System





### 健保雲端藥歷系統查詢結果

[回首頁](#)

1、本系統資料不含自費藥品且簡表藥品可能低報；資料傳輸會有24~48小時之時間落差。2、建議須向病人詢問藥品服用情形，方能掌握病人所有用藥品類。  
 3、本系統呈現之「主診斷」欄位係特約醫事服務機構醫療費用申報資料，僅供參考，確實診斷應以病歷記載為主。

身分證號： Z299\*\*\*965

查詢其他保險對象健保卡資料：

ATC5名稱

成份名稱

就醫區間

餘藥

藥品名稱

來源

本院  他院  藥局

項次	來源	主診斷	ATC5名稱	成份名稱	藥品 健保代碼	藥品名稱	藥品 規格 量	用法 用量	就醫日期 (住院用 藥起日)	慢連箋 領藥日 (住院用 藥迄日)	藥品 用量	給藥 日數	單筆 餘藥 日數 試算
1	他院 門診	SECONDARY SYPHILIS OF SKIN OR MUCOUS MEMBRANES	Solutions Affecting The Electrolyte Balance	Sodium Chloride	AC48699209	Ktolac Injection 30mg/MI (Ketorolac)	1ML		102/01/10		12	8	0
2	他院 門診	第二期(續發性)皮膚或黏膜梅毒	Solutions Affecting The Electrolyte Balance	Sodium Chloride	AC48699209	Ktolac Injection 30mg/MI (Ketorolac)	1ML		102/01/10		12	8	0
3	他院 門診	PRIMARY TUBERCULOUS COMPLEX. TUBERCLE BACILLI NOT FOUND BY BACTERIOLOGICAL EXAMINATION. BUT TUBERCULOSIS CONFIRMED HISTOLOGICALLY	Fluoroquinolones	Moxifloxacin	A019799212	Pyridoxal Phosphate Injection "Tai Yu"	2ML	IV	102/07/01	102/07/01	56	4	0
4	他院 門診	細菌學檢查未發現結核菌但組織學確認為結核病之原發性結核複合症	Fluoroquinolones	Moxifloxacin	A019799212	Pyridoxal Phosphate Injection "Tai Yu"	2ML	IV	102/07/01	102/07/01	56	4	0
5	他院 門診	細菌學檢查未發現結核菌但組織學確認為結核病之原發性結核複合症	Fluoroquinolones	Moxifloxacin	A019799212	Pyridoxal Phosphate Injection "Tai Yu"	2ML	IV	102/07/01	102/07/01	56	4	0
6	他院 門診	SECONDARY SYPHILIS OF SKIN OR MUCOUS MEMBRANES	Fluoroquinolones	Moxifloxacin	B023712265	Avelox Infusion Solution 400mg/250ml	250ML		102/01/01		56	4	0

source

active ingredient

drug code

drug name

date of prescribing

date of dispensing

drug days

diagnosis

constituent

Usage method

drug quantity

surplus



# Time-Line Graph and Pi Chart Display of Medication Record

查詢其他保險對象健保卡資料：  
摘要： 下列頁籤表示此健保對象有該項目資料

用藥紀錄明細 顯示設定

時間軸圖  最近3個月用藥紀錄來源  最近3個月就醫主要診斷  最近3個月同成分藥品使用情形 還原預設值 確定

雲端瀏覽 牙科處置及手術

1、本圖形化介面不含自費藥品、日劑與費醫令資料，且簡表藥品可能低報，實際用藥資料應以病歷記載為主；資料傳輸有24~48小時之時間落差。  
2、建議須向病人詢問藥品服用情形，方能掌握病人所有用藥品項。  
3、持慢性病連續處方箋調劑，須於給藥日期屆滿前十日內，始得再次調劑。  
4、用藥品項時間軸概念係參考臺中藥民總醫院院內用藥管理系統。

用藥紀錄明細 顯示設定

Today


2016	2017	2017	2017	2017	2017	2017	2017	2017	2017	2017
12-26	01-09	01-23	02-06	02-20	03-06	03-20	04-03	04-17	05-01	05-15
抗組胺藥 (A... PIPERA...										
咳嗽及感冒用... 咳嗽及感冒...										
OPILUM 咳嗽及感冒...										
OTHER 鼻部用藥 (N...										
SYMPAT... 止痛藥 (An...										
ANILID... 消炎藥及抗風...										
FENAMA... 消炎藥及抗風...										
ACETIC... 抗菌藥 (An...										
PENICI... 皮質類固醇 (...										
GLUCOC...										

抗組胺藥 (Antihistamines for systemic use)  
PIPERAZINE DERIVATIVES  
LEVOZINE F.C. TABLETS 5MG\*STANDARD\*(LEVOCETIRIZINE DIHYDROCHLORIDE)  
他院門診 QD 5天  
2017/02/20 - 2017/02/25


最近 3 個月用藥紀錄來源



最近 3 個月就醫主要診斷



最近 3 個月同成分藥品使用情形





# Medical Examination Record

身分證號： H22 201

查詢其他保險對象健保卡資料：

摘要： 下列頁籤表示此健保對象有該項目資料。

雲端藥歷    檢查檢驗    牙科處置及手術

請移動滑鼠至診療部位代碼即可顯示名稱

顯示欄位設定    查詢    清除

項次	來源	費用年月	就醫科別	主診斷名稱	檢查項目	醫令代碼	醫令名稱	診療部位	執行時間-起 (收件日期)	執行時間-迄 (檢驗報告日期)	醫令總量
1	他院門診 153 .108	105/08	婦產科	急性膀胱炎未伴有血尿	尿液檢查	06012C	General urine examination		105/08/21	105/08/21	1
2	他院門診 153 .049	105/08	內分泌科	第一型糖尿病，未伴有併發症	生化學檢查	09005C	Glucose		105/07/01	105/08/14	1
3	他院門診 153 .049	105/08	內分泌科	第一型糖尿病，未伴有併發症	生化學檢查	09006C	HbA1c (Hemoglobin A1c)		105/07/01	105/08/14	1
4	他院門診 153 .108	105/07	婦產科	急性膀胱炎未伴有血尿	尿液檢查	06012C	General urine examination		105/07/27	105/07/27	1
5	他院門診 153 .108	105/07	婦產科	急性膀胱炎未伴有血尿	尿液檢查	06012C	General urine examination		105/07/23	105/07/23	1



# Medical Examination Results

衛生福利部中央健康保險署 - Windows Internet Explorer 是由下列提供: [衛生福利部中央健康保險署]

醫令名稱

Order code

Date of examination

Result


Order name

Reference value

醫令代碼	醫令名稱	採檢日期	105/09/19				
09001C	總膽固醇	採檢日期	105/09/19				
		結果值	150.000 mg/dl				
		參考值	2.000- 200.000				
醫令代碼	醫令名稱	採檢日期	105/10/14	105/10/11	105/10/05	105/10/05	105/09/30
09002C	血中尿素氮	採檢日期	105/10/14	105/10/11	105/10/05	105/10/05	105/09/30
		結果值	40.100 mg/dl	39.600 mg/dl	35.200 mg/dl	56.900 mg/dl	40.300 mg/dl
		參考值	5.000- 20.000	5.000- 20.000	5.000- 20.000	5.000- 20.000	5.000- 20.000
醫令代碼	醫令名稱	採檢日期	105/09/28	105/09/19	105/09/19	105/09/11	105/09/11
09002C	血中尿素氮	採檢日期	105/09/28	105/09/19	105/09/19	105/09/11	105/09/11
		結果值	43.800 mg/dl	22.600 mg/dl	44.200 mg/dl	68.1 mg/dL	92.9 mg/dL
		參考值	5.000- 20.000	5.000- 20.000	5.000- 20.000	6-21	6-21
醫令代碼	醫令名稱	採檢日期	105/09/11	105/09/09	105/09/05	105/08/29	105/08/26
09002C	血中尿素氮	採檢日期	105/09/11	105/09/09	105/09/05	105/08/29	105/08/26
		結果值	92.9 mg/dL	94 mg/dL	114 mg/dL	115 mg/dL	95 mg/dL
		參考值	6-21	5- 23 *	5- 23 *	5- 23 *	5- 23 *
醫令代碼	醫令名稱	採檢日期	105/08/21	105/08/19	105/07/26	105/07/22	
09002C	血中尿素氮	採檢日期	105/08/21	105/08/19	105/07/26	105/07/22	
		結果值	112 mg/dL	64 mg/dL	38 mg/dL	78 mg/dL	
		參考值	5- 23 *	5- 23 *	5- 23 *	5- 23 *	
醫令代碼	醫令名稱	採檢日期	105/09/19				
09004C	三酸甘油酯	採檢日期	105/09/19				
		結果值	268.000 mg/dl				
		參考值	2.000- 200.000				
醫令代碼	醫令名稱	採檢日期	105/10/16	105/10/05	105/09/19	105/07/22	105/09/12
09005C	血液及體液葡萄糖	採檢日期	105/10/16	105/10/05	105/09/19	105/07/22	105/09/12
		結果值	666.000 mg/dl	195.000 mg/dl	350.000 mg/dl	316 mg/dL	F/S213mg/dL mg/dL
		參考值	70.000- 100.000	70.000- 100.000	70.000- 100.000	< 200 *	70-100
醫令代碼	醫令名稱	採檢日期	105/09/12	105/09/12	105/09/12	105/09/12	105/09/12
		結果值	F/S : 121mg/dL mg/dL	F/S : 130mg/dL mg/dL	F/S : 184mg/dL mg/dL	F/S : 197mg/dL mg/dL	F/S : 197mg/dL mg/dL

# Impacts of NHI Medi-cloud system (1/2)


■ the Rate of NHI Medcloud-inquired patients grow up quarterly




# Impacts of NHI Medi-cloud system (2/2)

■ Percentage changes in overlapping days of drugs of identical pharmacodynamics for six chronic diseases


## Anti-hypertension drugs




## Lipid modifying agents




## Drugs for diabetes




## Drugs for schizophrenia



## Drugs for depression



## Hypnotics and sedatives





*These are we have done and are doing*

***Thank you  
for your kind attention!***